The company’s stock rose significantly after it announced the full Phase I/II data. Image credit: Lightspring / Shutterstock.com. Intensity Therapeutics’ stock has risen nearly 400% after its oncology ...
While AstraZeneca’s gefurulimab met its primary and secondary endpoints in generalised myasthenia gravis (gMG), the drug failed to best AstraZeneca’s other approved medications, Soliris and Ultomiris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback